Renaissance Capital logo

NVLS News

US IPO Weekly Recap: 8 companies go public as Fitbit runs up 63%

FIT

Eight IPOs raised $2.3 billion this past week. High-growth consumer deals Fitbit and Fogo de Chão came out on top. This week featured a diverse set technology, consumer, energy, health care and industrial IPOs, none of which priced below the proposed midpoint. The largest first-day pops and drops tend to come from smaller companies, but Fitbit ($5 billion...read more

Nivalis Therapeutics prices upsized IPO at $14 midpoint

Nivalis Therapeutics, which is developing a complementary small molecule therapy for cystic fibrosis, raised $77 million in an upsized IPO by offering 5.5 million shares at $14, the midpoint of the range of $13 to $15. The company originally planned to sell 4.3 million shares. Existing investors planned to buy $25 million on the IPO, representing 32% of the deal. Nivalis...read more

Week ahead: Fitbit and 10 more IPOs planned for the week of June 15

FIT

Fitbit leads this week's 11 companies looking to raise over $1.7 billion through US initial public offerings. A good FIT Fitbit (FIT) flexes its muscle with the week's largest IPO; the deal size is set at $448 million, though it could raise more based on investor demand. Fitbit has...read more

Cystic fibrosis biotech Nivalis Therapeutics sets terms for $60 million IPO

Nivalis Therapeutics, which is developing a complementary small molecule therapy for cystic fibrosis, announced terms for its IPO on Wednesday. The Boulder, CO-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Nivalis Therapeutics would command a fully diluted market value of $200...read more